Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development and formulation, contract manufacturing, and project management. Samsung Biologics cell culture development process includes upstream, downstream and analytical technology. Samsung Biologics’ provides manufacturing and quality assurance for clinical and commercial products. In addition, the company also offers infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products. Samsung Biologics also offers biosafety testing and analytical testing services. It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.
Headquarters
South Korea
Address
300, Songdo Bio-Daero, Yeonsu-Gu, Incheon, 21987
Website
samsungbiologics.com
Telephone
82 32 4553114
No of Employees
2,587
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
207940 ()
Revenue (2021)
$1.4B
34.6%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
63.3%
(2021 vs 2020)
Market Cap*
$45.5B
Net Profit Margin (2021)
XXX
21.3%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Services |
|---|
| Services |
| Process Development: |
| Upstream Process Development |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Acquisitions/Mergers/Takeovers | In April, the company acquired Biogen’s stake in the Samsung Bioepis joint venture for US$2.3 billion. |
| 2022 | Financing Agreements | In April, the company along with a biotech division announced to raise US$2.6 billion in a rights offering for existing shareholders. |
| 2022 | Plans/Strategy | In March, the company announced its plans to purchase a land site to construct its fifth and sixth plants in Songdo, Incheon. |
Competitor Comparison
| Key Parameters | Samsung Biologics Co Ltd | Celltrion Healthcare Co Ltd | ToolGen Inc | Ensol Biosciences Inc | Biterials Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Incheon | Incheon | Seoul | Daejeon | Yongsan-gu |
| State/Province | - | - | - | - | Seoul |
| No. of Employees | 2,587 | - | 71 | 45 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kim Tae-han | Chairman | Executive Board | 2011 | 64 |
| John Rim | Chief Executive Officer; Director; President | Executive Board | 2020 | 60 |
| Dongjoong Kim | Director; Chief Financial Officer; Managing Director; Senior Vice President | Executive Board | 2014 | 56 |
| Sam Machour | Senior Vice President | Senior Management | 2019 | 58 |
| Yang Eunyoung | Vice President | Senior Management | 2018 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer